Yuhong Li
22 Papers
4 Citations
Yuhong Li is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
Qi Zhao,Feng Hua Wang,Yan-Xing Chen,Shifu Chen,Yi-Chen Yao,Zhaolei Zeng,Teng-Jia Jiang,Ying-Nan Wang,Chen-Yi Wu,Ying Jing,You-Sheng Huang,Jing Zhang,Zi-Xian Wang,Ming Ming He,Heng-Ying Pu,Zong-Jiong Mai,Qi-Nian Wu,Renwen Long,Xiao Zhang,Tanxiao Huang,Min-Jun Xu,Miao Qiu,Hui Yan Luo,Yuhong Li,Dong-shen Zhang,Wei Hua Jia,Gong Chen,Pei-Rong Ding,Liren Li,Zhenhai Lu,Zhizhong Pan,Rui-Hua Xu +31 more
TL;DR: Wang et al. as discussed by the authors performed ultradeep whole-exome sequencing on 1015 patients with colorectal cancer and identified 46 high-confident significantly mutated genes, 8 of which mutate in 14.9% of patients: Lysst, DAPK1, CR2, KIF16B, NPIPB15, SYTL2, ZNF91, and KIAA0586.
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
Liu-Fang Ye,Zi-Yao Huang,Xiaoxi Chen,Zhi Gang Chen,Siting Wu,Chao Ren,Ming-Tao Hu,Hua Bao,Ying Jin,Feng Hua Wang,Fenghua Wang,Ziming Du,Xue Wu,Huai-Qiang Ju,Yang W. Shao,Yuhong Li,Rui-Hua Xu,De Shen Wang +17 more
TL;DR: In this article , the authors identify mechanisms of drug resistance to the combination of vemurafenib, irinotecan, and cetuximab (VIC) in BRAFV600E metastatic colorectal cancer (mCRC).
17
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.
Yan-Xing Chen,Zi-Xian Wang,Ying Jin,Qi Zhao,Zexian Liu,Zhixiang Zuo,Huai-Qiang Ju,Chengxu Cui,Jun Yao,Yanqiao Zhang,Mengxia Li,Jifeng Feng,Lin Tian,Xiaojun Xia,Hui Feng,Sheng Yao,Fenghua Wang,Yuhong Li,Feng Hua Wang,Rui-Hua Xu +19 more
TL;DR: In this paper , the authors performed whole-exome sequencing on tumor samples from 486 patients of the JUPITER-06 study and developed a copy number alteration-corrected tumor mutational burden that depicts immunogenicity more precisely and predicts chemo+anti-PD-1 efficacy.
17
Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer
Zexian Liu,Xiaolong Zhang,Qi Zhao,Yungchang Chen,Hui Sheng,Caiyun He,Yu-Ting Sun,Ming-Yu Lai,Minqing Wu,Zhixiang Zuo,Wei Wang,Fenghua Wang,Yuhong Li,Rui-Hua Xu,Miao Zhen Qiu +14 more
TL;DR: Wang et al. as mentioned in this paper found that double-hit events may serve as important mechanisms for hereditary diffuse gastric cancer tumorigenesis; the study also provided a genetic landscape and identified new susceptibility genes for HDGC.
Platinums sensitize human epithelial tumor cells to lymphotoxin α by inhibiting NF-κB-dependent transcription
Yijun Shen,Jing Wang,Tong Yang,Yuhong Li,Wenqi Jiang,Zhongzhen Guan,Zheng Wang,Jingwei Tan,Jinsong Wu,Gang Li,Qing Xu,Fang Wu,Luochun Wang,Yanjun Liu +13 more
TL;DR: The results suggested that a proper combination of bio-agents such as LTα and conventional chemotherapeutic drugs such as platinums may be an efficient treatment strategy for human epithelial cancers.
12